Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 20

1.

A Study of Single Nucleotide Polymorphisms of the SLC19A1/RFC1 Gene in Subjects with Autism Spectrum Disorder.

Mahmuda NA, Yokoyama S, Huang JJ, Liu L, Munesue T, Nakatani H, Hayashi K, Yagi K, Yamagishi M, Higashida H.

Int J Mol Sci. 2016 May 19;17(5). pii: E772. doi: 10.3390/ijms17050772.

2.

Biology of the major facilitative folate transporters SLC19A1 and SLC46A1.

Hou Z, Matherly LH.

Curr Top Membr. 2014;73:175-204. doi: 10.1016/B978-0-12-800223-0.00004-9. Review.

3.

The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1: biology and role in antifolate chemotherapy of cancer.

Matherly LH, Wilson MR, Hou Z.

Drug Metab Dispos. 2014 Apr;42(4):632-49. doi: 10.1124/dmd.113.055723. Review.

4.

Uptake carriers and oncology drug safety.

Sprowl JA, Sparreboom A.

Drug Metab Dispos. 2014 Apr;42(4):611-22. doi: 10.1124/dmd.113.055806. Review.

5.

Contribution of tumoral and host solute carriers to clinical drug response.

Sprowl JA, Mikkelsen TS, Giovinazzo H, Sparreboom A.

Drug Resist Updat. 2012 Feb-Apr;15(1-2):5-20. doi: 10.1016/j.drup.2012.01.009. Review.

6.

Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity.

Hagos Y, Wolff NA.

Toxins (Basel). 2010 Aug;2(8):2055-82. doi: 10.3390/toxins2082055. Review.

7.

SLC19A1 pharmacogenomics summary.

Yee SW, Gong L, Badagnani I, Giacomini KM, Klein TE, Altman RB.

Pharmacogenet Genomics. 2010 Nov;20(11):708-15. doi: 10.1097/FPC.0b013e32833eca92. No abstract available.

8.
9.

Polymorphisms and methylation of the reduced folate carrier in osteosarcoma.

Yang R, Qin J, Hoang BH, Healey JH, Gorlick R.

Clin Orthop Relat Res. 2008 Sep;466(9):2046-51. doi: 10.1007/s11999-008-0323-3.

10.

Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrier.

Yang R, Li WW, Hoang BH, Kim H, Banerjee D, Kheradpour A, Healey JH, Meyers PA, Bertino JR, Gorlick R.

BMC Cancer. 2008 May 1;8:124. doi: 10.1186/1471-2407-8-124.

11.

Role of lysine 411 in substrate carboxyl group binding to the human reduced folate carrier, as determined by site-directed mutagenesis and affinity inhibition.

Deng Y, Hou Z, Wang L, Cherian C, Wu J, Gangjee A, Matherly LH.

Mol Pharmacol. 2008 Apr;73(4):1274-81. doi: 10.1124/mol.107.043190.

15.

Cytoplasmic domains of the reduced folate carrier are essential for trafficking, but not function.

Sadlish H, Williams FM, Flintoff WF.

Biochem J. 2002 Jun 15;364(Pt 3):777-86.

17.

Mutations in the reduced-folate carrier affect protein localization and stability.

Sadlish H, Murray RC, Williams FM, Flintoff WF.

Biochem J. 2000 Mar 1;346 Pt 2:509-18.

19.

Confocal microscopy visualization of antifolate uptake by the reduced folate carrier in human leukaemic cells.

Jolivet J, Faure MP, Wong SC, Taub JW, Matherly LH.

Br J Cancer. 1997;76(6):734-8.

20.

Endocytosis of GPI-linked membrane folate receptor-alpha.

Rijnboutt S, Jansen G, Posthuma G, Hynes JB, Schornagel JH, Strous GJ.

J Cell Biol. 1996 Jan;132(1-2):35-47.

Items per page

Supplemental Content

Support Center